Siqueira Scheyla D V S, Müllertz Anette, Gräeser Kirsten, Kasten Georgia, Mu Huiling, Rades Thomas
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 2100, Copenhagen, Denmark.
Roche Pharma Research and Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
AAPS J. 2017 Mar;19(2):587-594. doi: 10.1208/s12248-016-0038-4. Epub 2017 Jan 9.
The aim of this work was to evaluate the influence of drug load and physical form of cinnarizine (CIN) in self-nanoemulsifying drug delivery systems (SNEDDS) on absorption in rats. Further, the predictivity of the dynamic in vitro lipolysis model was evaluated. The following dosing regimens were assessed: (1) CIN dissolved in SNEDDS at 80% of equilibrium solubility (S) (SNEDDS 80%); (2) supersaturated SNEDDS with CIN dissolved at 200% S (super-SNEDDS solution); (3) SNEDDS suspension with CIN added at 200% S (CIN partially dissolved and partially suspended) (super-SNEDDS suspension); (4) drug-free SNEDDS co-dosed with aqueous CIN suspension (Chasing principle), and (5) CIN aqueous suspension. The CIN dose was kept constant for all dosing regimens. Therefore, the super-SNEDDS solution and super-SNEDDS suspension contained 2.5-fold less SNEDDS pre-concentrate than SNEDDS 80% and the Chasing principle. In vivo, a higher AUC after dosing CIN in SNEDDS 80% and the Chasing principle was obtained when compared to the super-SNEDDS solution, super-SNEDDS suspension, and aqueous suspension. In vitro, a higher extent of CIN in the aqueous phase was observed for all SNEDDS-containing dosing regimens, compared to the aqueous suspension. Since the drug level in the aqueous phase is traditionally considered as the fraction available for absorption, a lack of in vitro-in vivo relation was observed. This study revealed that the physical form of CIN in the current SNEDDS does not affect CIN absorption and solubilization, whereas the drug load, or amount of co-dosed lipid, significantly influenced CIN bioavailability.
本研究旨在评估桂利嗪(CIN)在自纳米乳化药物递送系统(SNEDDS)中的载药量和物理形态对大鼠体内吸收的影响。此外,还评估了动态体外脂解模型的预测能力。评估了以下给药方案:(1)CIN溶解于SNEDDS中,浓度为平衡溶解度(S)的80%(SNEDDS 80%);(2)CIN溶解于SNEDDS中,浓度为200% S的过饱和溶液(过饱和SNEDDS溶液);(3)CIN以200% S加入的SNEDDS混悬液(CIN部分溶解部分混悬)(过饱和SNEDDS混悬液);(4)与CIN水混悬液联合给药的无药SNEDDS(追赶原理),以及(5)CIN水混悬液。所有给药方案中CIN的剂量保持恒定。因此,过饱和SNEDDS溶液和过饱和SNEDDS混悬液中SNEDDS预浓缩物的含量比SNEDDS 80%和追赶原理中的少2.5倍。在体内,与过饱和SNEDDS溶液、过饱和SNEDDS混悬液和水混悬液相比,给予80% SNEDDS和追赶原理的CIN后获得了更高的AUC。在体外,与水混悬液相比,所有含SNEDDS的给药方案在水相中的CIN含量更高。由于传统上认为水相中的药物水平是可吸收的部分,因此观察到体外-体内关系缺乏。本研究表明,当前SNEDDS中CIN的物理形态不影响CIN的吸收和溶解,而载药量或联合给药的脂质用量显著影响CIN的生物利用度。